Dr. Mark Johnson

Mark W. Johnson, MD

Professor, Ophthalmology and Visual Sciences
Section Leader, Retina and Uveitis
Academic Office: 734-615-2479

Areas of Interest

Research Summary

Pathogenesis and treatment of macular holes and other vitreomacular conditions; anti-angiogenic and intraocular anti-inflammatory drug therapy; techniques and outcomes of macular and submacular surgery; gene studies of age-related macular degeneration; evolution and complications of PVD; pathogenesis of neuromaculopathies

Dr. Mark Johnson is principal investigator at the Kellogg Eye Center for several multicenter clinical trials examining the safety and efficacy of new treatments for neovascular age-related macular degeneration (AMD), including novel anti-angiogenic drugs such as VEGF inhibitors. He is also principal investigator for the NEI-sponsored SCORE study, which investigates intravitreal corticosteroid treatment for retinal vein occlusions. He serves on Data and Safety Monitoring Committees for multicenter clinical trials comparing Lucentis to Avastin for neovascular AMD and investigating the use of RNA interference agents in patients with AMD. Other projects at the Kellogg Eye Center are studying the duration of action of bevacizumab, the long-term safety of repeated intravitreal injections of anti-VEGF agents, the phenomenon of possible tolerance to VEGF-inhibiting drugs, vitreous penetration of oral antiviral drugs, and optimal surgical strategies for repair of pseudophakic retinal detachment.

Dr. Johnson is also interested in the pathogenesis and treatment of vitreomacular disorders. He has carried out clinical investigations which have further clarified the cause of macular hole, vitreomacular traction syndromes, epiretinal membrane, and optic pit maculopathy. An ongoing study is looking at the clinical characteristics and postsurgical outcomes in the vitreofoveolar traction syndrome, a subtle variant of the vitreomacular traction syndrome.

Clinical Interests

Macular diseases; retinal vascular disorders and diabetic retinopathy; posterior segment inflammatory disorders; vitreoretinal surgery; macular and submacular surgery; pharmacologic adjuncts for vitreoretinal surgery; anti-angiogenic therapy; photodynamic therapy

Subspecialty: Retina

Make an Appointment

Honors & Awards


  • Planning committee, Retina Subspecialty Day, American Academy of Ophthalmology


  • Best Doctors in America
  • Castle Connolly Top Doctor
  • Retina 150, Ocular Surgery News
  • Lifetime Achievement Honor Award, American Academy of Ophthalmology (AAO)
  • Credentials Committee, Macula Society
  • Editorial board, Retina
  • Editorial board, American Journal of Ophthalmology
  • President, The Retina Society
  • A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study, INC Research


  • Medical School - University of Utah, 1984
  • Residency - Ophthalmology, Kellogg Eye Center, University of Michigan, 1988
  • Fellowships
    • Macular Diseases, Bascom Palmer Eye Institute, University of Miami, 1989
    • Vitreo-Retinal Diseases and Surgery, Bascom Palmer Eye Institute, University of Miami, 1990

Published Articles or Reviews

Web Sites